UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 1,651 Shares of Exelixis, Inc. $EXEL

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 0.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 845,996 shares of the biotechnology company’s stock after buying an additional 1,651 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.31% of Exelixis worth $31,234,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the company. Frank Rimerman Advisors LLC raised its position in shares of Exelixis by 4.7% during the first quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 307 shares during the period. Rathbones Group PLC grew its stake in shares of Exelixis by 5.3% during the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 347 shares during the period. Larson Financial Group LLC boosted its stake in Exelixis by 9.2% in the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 367 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Exelixis by 14.8% in the 1st quarter. Smartleaf Asset Management LLC now owns 3,378 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 436 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EXEL. Wall Street Zen downgraded Exelixis from a “buy” rating to a “hold” rating in a research note on Monday. William Blair reissued an “outperform” rating on shares of Exelixis in a report on Tuesday, July 29th. Barclays lifted their price target on Exelixis from $29.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 10th. Truist Financial reduced their target price on Exelixis from $56.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. Finally, Bank of America boosted their target price on Exelixis from $45.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 5th. Thirteen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $44.06.

Exelixis Stock Performance

Shares of EXEL stock opened at $39.01 on Tuesday. The stock has a fifty day simple moving average of $39.87 and a two-hundred day simple moving average of $39.66. Exelixis, Inc. has a 52-week low of $25.17 and a 52-week high of $49.62. The firm has a market capitalization of $10.50 billion, a PE ratio of 18.75, a PEG ratio of 0.81 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $568.26 million during the quarter, compared to the consensus estimate of $574.36 million. During the same quarter in the prior year, the firm earned $0.84 EPS. The business’s revenue was down 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.